Laboratory Corporation of America Holdings (LabCorp) has announced that Covance Drug Development has launched Mobile Health Solutions, a suite of new capabilities designed to help biopharmaceutical and technology companies navigate the rapidly evolving mobile health landscape. Covance’s Mobile Health Solutions suite provides regulatory consulting and validation services to help companies certify the accuracy and consistency of mobile devices and applications for use in clinical trials.
“Mobile technology is changing the way patients interact with their healthcare providers, and clinical trials must adapt as well,” said Deborah Keller, chief executive officer of Covance. “Covance has the expertise and scale to help our partners evaluate which apps and devices will be most effective, will generate the most consistent and reliable data and will be easy for patients to use.”
Mobile health devices and apps may be used in a variety of ways to help enhance patient access, produce longitudinal data measurements and generate more powerful data analytics, which all contribute to innovative clinical research. However, the use of mobile technologies requires a clear understanding of rapidly evolving regulations and emerging new devices. Covance regulatory experts help clients determine pathways for mobile health validation, registration and approval for use in clinical trials, and Covance’s network of early phase development clinics provides necessary environmental controls and robust biometric analysis to drive reliable device and app validation.
“Covance is committed to helping clients leverage mobile technology to improve the success of clinical trials and enhance the patient experience,” said Keller. “Our Mobile Health Solutions support our strategic vision to improve health and improve lives through the use of technology-enabled solutions that enhance the drug-development process and can reduce the time and cost of trials.”